Light Genferon® 10000 IU / ml + 0.8 mg / ml 10 ml nasal drops

The instruction for medical use of LIGHT GENFERON® medicine the Trade name of Genferon® the light International unlicensed name Is not present the Dosage form of the Drop nasal, 10,000 ME, 10 ml Structure of 1 ml of solution contain active agents - interferon alpha 2b human recombinant (рчИФН-α2b) 10,000 ME, taurine of 0.80 mg, excipients: edetat dinatrium a dihydrate, glitserol, a dextran 35000-45000, polysorbate-80, sodium chloride, potassium chloride, sodium hydrophosphate, potassium dihydrophosphate, water for injections. Excipients according to FSP JSC BIOCAD, Russia are a part of Interferon Alpha 2b Human Recombinant (рчИФН-α2b) substance: sodium chloride (EF *), acetate sodium trihydrate (EF *), ice acetic acid (EF *), water for injections (EF *). * - the existing Description Transparent edition colourless or light yellow color liquid. Pharmacotherapeutic group Immunomodulators. Immunostimulators. Interferona. Interferon alpha 2b. The ATX L03AB05 code the Pharmacological Pharmacokinetics At properties intranasal use the drug Genferon® light, drops nasal, creates high concentration of interferon in the center of an infection and renders expressed the local antiviral and immunostimulating effect. System absorption of drug is insignificant, at intranasal introduction interferon human recombinant alpha 2b in a small amount is defined in pulmonary fabric and blood. In an organism the biotransformation happens mainly in kidneys to elimination half-life (Т½) 5.1 hours. The small amount of drug getting to a system blood stream renders system immunomodulatory effect. The pharmacodynamics the Drug Genferon® light, drops nasal, renders antiviral, immunomodulatory, anti-inflammatory, anti-proliferative, antibacterial action, has the local regenerating, membrane stabilizing and antioxidant properties. Interferon the alpha blocks reproduction of viruses at a stage of synthesis of specific proteins and prevents infection of not infected cells of a mucous membrane of a nasal cavity, being the place of an invasion of activators and primary center of inflammation in respiratory infections. Immunomodulatory action is shown by strengthening of cell-mediated reactions of the immune system that increases efficiency of the immune response concerning alien agents. It is reached due to activation of CD8+ of T-killers, NK cells (natural killers), strengthening of a differentiation of V-lymphocytes and products of antibodies by them, activation of a monocytic and macrophagic system and phagocytosis and also increase in an expression of molecules of the main complex of histocompatability of the I type that increases the probability of recognition of the infected cells cells of the immune system. Activization under the influence of interferon of the leukocytes which are contained in all layers of a mucous membrane provides their active participation in elimination of the pathological centers, besides, due to influence of interferon the restoration of products of secretory immunoglobulin A is reached. The antibacterial effect is mediated by the reactions of the immune system strengthened under the influence of interferon. The taurine which is a part of drug normalizes metabolic processes in fabrics, promotes regeneration and faster recovery of a mucous membrane of the nasal cavity injured by pathological process. Indications - treatment of flu and other acute respiratory viral infections at children aged from 29 days up to 14 years light dig in the Route of administration and doses At the first symptoms of a disease of Genferon® in a nose within 5 days. To children aged from 29 days up to 11 months 29 days – on 1 drop in each nasal course of 5 times a day (single dose of 1,000 ME, a daily dose of 5,000 ME). To children aged from 1 year up to 3 years – on 2 drops in each nasal course 3 – 4 times a day (single dose of 2,000 ME, a daily dose of 6,000 - 8,000 ME). To children aged from 3 up to 14 years – on 2 drops in each nasal course of 4 - 5 times a day (single dose of 2,000 ME, a daily dose of 8,000 - 10,000 ME). Side effects Very seldom - are possible local allergic reactions (burning sensation, an itching) These phenomena are reversible and disappear independently within 72 hours after drug phase-out. Continuation of treatment is possible only after consultation with the doctor. The contraindication - individual intolerance or hypersensitivity to interferon alpha 2b or to other components of drug - newborns from 0 to 28 days (in view of lack of clinical data) - severe forms of allergic diseases Medicinal interactions is not recommended simultaneous use of intranasal vasoconstrictive drugs as it causes additional dryness of a mucous membrane of a nasal cavity. Special instructions After burying it is recommended to massage fingers nose wings within several minutes for hypodispersion of drug in a nasal cavity. Pregnancy and the period of a lactation is not used as drug is shown for use for children aged from 29 days up to 14 years. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Influence of the drug Genferon® of potentially dangerous types of activity, light on performance, requiring special attention and fast reactions (control of vehicles, the machine equipment) it was not studied. Overdose Cases of overdose of the drug Genferon® light are not registered so far. Form of release and packing of the Drop nasal, 10,000 ME, 10 ml. On 10 ml in the bottles of dark glass which are hermetically corked by traffic jams with a running in aluminum caps. On each bottle paste the label self-adhesive. On 1 bottle complete with 1 nozzle dropper, together with the instruction for medical use in the state and Russian languages in a pack from cardboard. On 10 ml in the bottles of dark glass which are hermetically corked by nozzles droppers. On each bottle paste the label self-adhesive. On 1 bottle together with the instruction for medical use in the state and Russian languages in a pack from cardboard. To Store storage conditions in the dry, protected from light place at a temperature from 2 to 8 °C. After opening of a bottle to store within 7 weeks at a temperature from 2 to 8 °C. To store out of children's reach. Period of storage 2 years. Not to use after the expiration date specified on packing. Prescription status According to the prescription. Producer/packer of JSC BIOCAD, Russian Federation. Legal address: Russian Federation, 198515, St. Petersburg, Petrodvorets district, item Strelna, Svyazi St., 34A. Location address: Russian Federation, 143422, Moscow region, Krasnogorsk district, village of Petrovo-Dalneye, phone number: +7 (495) 992-66-28, fax: +7 (495) 992-82-98, e-mail: biocad@biocad.ru Holder of the registration certificate of JSC BIOCAD, Russian Federation. The name and the address of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines from consumers the Representative of the BIOKAD company Republic of Kazakhstan, 010000, Astana, Orynbor St., 21/1-15. Ph.: 8 (7172) 63-40-15, +7 (812) 380-49-33 E-mail: rahimbaeva@biocad.ru, biocad@biocad.ru, website: www.biocad.ru. The name and the address of the organization in the territory of the Republic of Kazakhstan responsible for post-registration observation of safety of medicine the Representative of the BIOKAD company Republic of Kazakhstan, 010000, Astana, Orynbor St., 21/1-15. E-mail: rahimbaeva@biocad.ru, safety@biocad.ru, biocad@biocad.ru